New York, New York (PRWEB) January 08, 2014
As Lipitor lawsuits (http://www.thelipitorlawsuit.com) continue to mount in courts around the country, Bernstein Liebhard LLP notes the publication of a new study that has found a possible explanation for the link between statins like Lipitor and the development of Type 2 diabetes. The research, which appears in the journal Diabetes, Obesity, and Metabolism, found that some statins may reduce levels of a hormone called adiponectin, which the authors of the study say could result in islet cell dysfunction and insulin resistance. They further point out that only one statin – pitavastatin – has been seen to increase adiponectin levels, and it is the only medication in that class that has not been linked to an increased risk of new-onset diabetes.*
“We are currently investigating a number of legal claims on behalf of individuals who allegedly developed Type 2 diabetes due to their use of Lipitor. This study provides valuable insight regarding the possible mechanism behind their alleged injuries,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to anyone who may have developed new-onset Type 2 diabetes due to the use of this statin medication.
Lipitor and Diabetes
In January 2012, research published in JAMA: Internal Medicine reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes.** A month later, the U.S. Food & Drug Administration (FDA) ordered that new warnings be added to the labels of Lipitor and other statins regarding their possible association with the disease.
In May 2013, a study published in the British Medical Journal confirmed the possible link between Lipitor and diabetes, finding that use of the drug was associated with a 22 percent increased risk of new-onset diabetes.***
Since the FDA issued its alert in February 2012, numerous individuals have filed Lipitor lawsuits that allege their use of the statin resulted in a diagnosis of Type 2 diabetes. According to court documents, the U.S. Judicial Panel will hear oral arguments on January 30th regarding the possible consolidation of federally-filed Lipitor diabetes claims in a single jurisdiction for pretrial proceedings. The hearing will mark the second time the Panel has taken up this matter, as it rejected a previous request from plaintiffs in April on the grounds that there were not sufficient filings to warrant the establishment of a multidistrict litigation. However, in their second request seeking consolidation of Lipitor lawsuits, plaintiffs point out that at least 100 complaints involving diabetes allegations are now pending in federal courts around the country. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
Individuals who allegedly developed Type 2 diabetes due to their use of Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*onlinelibrary.wiley.com/doi/10.1111/dom.12254/abstract; Diabetes, Obesity, and Metabolism, December 24, 2013
**archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
***bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com